Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

ClinicalTrials.gov ID: NCT06436703

Public ClinicalTrials.gov record NCT06436703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign. RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid. Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat. The study is seeking for participants who: * are at least 18 years of age * have not received an influenza vaccine within the last 6 months * are generally healthy This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC). All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm: * 1 of the modRNA influenza vaccines that is being studied; or * an approved influenza vaccine approved for use in their respective age group. Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.

Study identification

NCT ID
NCT06436703
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
1,202 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 22, 2024
Primary completion
Feb 4, 2025
Completion
Feb 4, 2025
Last update posted
Jun 11, 2026

2024 – 2025

United States locations

U.S. sites
32
U.S. states
15
U.S. cities
28
Facility City State ZIP Site status
AMR Clinical Mobile Alabama 36608
Headlands Research - Scottsdale Scottsdale Arizona 85260
Anaheim Clinical Trials, LLC Anaheim California 92801
Orange County Research Center Lake Forest California 92630
Artemis Institute for Clinical Research San Diego California 92103
Diablo Clinical Research, Inc. Walnut Creek California 94598
Clinical Research Consulting Milford Connecticut 06460
Indago Research & Health Center, Inc Hialeah Florida 33012
Research Centers of America ( Hollywood ) Hollywood Florida 33024
Research Centers of America Hollywood Florida 33024
Palm Springs Community Health Center Miami Lakes Florida 33014
Clinical Neuroscience Solutions, Inc. Orlando Florida 32801
Headlands Research Orlando Orlando Florida 32819
Qps-Mra, Llc South Miami Florida 33143
East-West Medical Research Institute Honolulu Hawaii 96814
Alliance for Multispecialty Research, LLC New Orleans Louisiana 70119
Prism Research LLC dba Nucleus Network Saint Paul Minnesota 55114
Clinical Research Professionals Chesterfield Missouri 63005
Alliance for Multispecialty Research, LLC Kansas City Missouri 64114
Rochester Clinical Research, LLC Rochester New York 14609
Duke Vaccine and Trials Unit Durham North Carolina 27703
M3 Wake Research, Inc. Raleigh North Carolina 27612
DM Clinical Research - Philadelphia Philadelphia Pennsylvania 19107
Headlands Horizons LLC Brownsville Texas 78526
SMS Clinical Research Mesquite Texas 75149
Clinical Trials of Texas, LLC dba Flourish Research San Antonio Texas 78229
Clinical Trials of Texas, LLC San Antonio Texas 78229
Dynamed Clinical Research, LP d/b/a DM Clinical Research Tomball Texas 77375
J. Lewis Research, Inc. / Foothill Family Clinic Salt Lake City Utah 84109
J. Lewis Research, Inc. / Foothill Family Clinic South Salt Lake City Utah 84121
Charlottesville Medical Research Charlottesville Virginia 22911
AMR Clinical Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06436703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2026 · Synced Sep 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06436703 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →